MedTrace Logo

The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD.

NCT03752918 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2026-05-19

No results posted yet for this study

Summary

This study aims to investigate the effects of MDMA on prefrontal and amygdala activation, and to explore the relationship between these MDMA-induced neural changes and the acute behavioral effects of the drug in patients with PTSD.

Conditions

  • Post Traumatic Stress Disorder

Interventions

DRUG

MDMA

A single dose of 1.5mg/kg will be administered once orally.

DRUG

Niacin

A single dose of 250mg will be administered once orally.

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Benjamin Kelmendi, MD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-31
Primary Completion
2028-01-31
Completion
2028-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03752918 on ClinicalTrials.gov